Accuray Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARAY research report →
Range $2 – $2
Price Chart
About the company
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy.
- CEO
- Stephen R. LaNeve
- IPO
- 2007
- Employees
- 809
- HQ
- Madison, WI, US
Get TickerSpark's AI analysis on ARAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.22M
- P/E
- -0.36
- PEG
- 0.00
- P/S
- 0.02
- P/B
- 0.13
- EV/EBITDA
- 3.63
- Div Yield
- 0.00%
- Gross Margin
- 28.13%
- Op Margin
- -13.09%
- Net Margin
- -4.41%
- ROE
- -36.60%
- ROIC
- -22.02%
Latest fiscal year · YoY change
- Revenue
- $401.95M-12.3%
- Gross Profit
- $111.45M-24.2%
- Op Income
- $-26,442,000
- Net Income
- $-49,194,000-2992.0%
- EPS
- $-16.00-2480.6%
- OCF Growth
- -344.1%
- FCF Growth
- -126.8%
- 52W High
- $45.20
- 52W Low
- $2.04
- 50D MA
- $6.92
- 200D MA
- $12.64
- Beta
- 1.38
- RSI (14)
- 19
- Avg Volume
- 201.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Accuray posted lower Q1 revenue and product orders, but service growth, margin expansion, and a lower cost base showed its transformation is taking hold.· November 4, 2026
- Revenue fell 8% to $86.5 million as product sales were hit by geopolitical and market issues in China.
- Service revenue rose 4% to $59.2 million and service gross margin improved to 35.1%, up from 33.9% a year ago.
- Product revenue dropped 26% to $27.3 million; product gross orders were $19.8 million and book-to-bill was 0.7.
- Operating costs excluding restructuring were down about $13 million year over year, reflecting the company’s lower structural cost base.
- Management highlighted strategic partnerships with RaySearch and Samsung NeuroLogica to strengthen adaptive therapy and imaging capabilities.
Net revenue was $86.5 million, down $7.4 million or 8% year over year, and down 7% on a constant currency basis. Service revenue increased 4% to $59.2 million, while product revenue declined 26% to $27.3 million. Gross profit was $26.1 million with gross margin of 30.1%, versus 28.8% in the prior year; service gross margin was 35.1% versus 33.9%, and product gross margin was 19.4% versus 20.8%. Operating expenses were $62.6 million, including a $35.4 million noncash goodwill impairment charge; excluding goodwill impairment and restructuring, operating expenses were $26.8 million, down 25%. Operating loss was $36.5 million, adjusted EBITDA was $2.5 million versus a loss of $4.1 million a year ago, and the company recognized a $59.6 million gain on extinguishment of debt. Cash, cash equivalents and restricted cash were $50.4 million at quarter end. Product gross orders were $19.8 million, book-to-bill was 0.7, trailing 12-month book-to-bill was 1.1, and reported backlog was about $272 million. Management did not provide formal guidance for next quarter or full year.
Steve LaNeve framed fiscal 2027 as a year of execution after fiscal 2026’s transformation work. He said the company has strengthened its financial foundation, lowered costs, improved the organization, and sharpened commercial focus, but acknowledged that product orders and revenue missed expectations, especially because of China. He emphasized that Accuray’s installed base, recurring service revenue, and innovation strategy around adaptive therapy and imaging are key to long-term growth and profitability.
Ali Pervaiz said the quarter showed better underlying economics even as product volume remained weak. He pointed to service revenue growth, a 35.1% service margin, and roughly $13 million of year-over-year bottom-line improvement from cost actions; excluding goodwill impairment and restructuring, operating expenses fell to $26.8 million. He also highlighted liquidity and balance-sheet actions, including $50.4 million of cash and restricted cash, $5 million outstanding on the revolver, a $15 million TCW cash investment during the quarter, and the planned exchange of $40 million of term loan debt for convertible preferred equity.
There was no analyst Q&A session; the operator said there were no questions. As a result, the call did not surface additional analyst concerns or management responses beyond the prepared remarks. The main issues already addressed were weak product orders, China-related headwinds, and the company’s reliance on service growth and execution improvements.
The bull case from the call is that Accuray is building a more durable business around its installed base, with recurring annual revenue above $230 million and improving service margins. Management also sounded confident that cost reductions, strategic partnerships, and a stronger balance sheet can create operating leverage once product orders recover.
The bear case is that product revenue and orders are still weak, with book-to-bill at 0.7 and China weighing on sales. The company also recorded a $35.4 million goodwill impairment and said product performance must improve to translate the cost reset and service strength into broader profitability.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.1%
- Shares Outstanding
- 3.00M
- Float Shares
- 2.85M
of shares held by institutions
112 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tcw Group Inc | 27.53M | ▲ 8.59M |
| Vanguard Group Inc | 5.82M | ▲ 341.90K |
| Armistice Capital, LLC | 5.74M | 0 |
| Neuberger Berman Group LLC | 5.38M | ▼ 688.85K |
| Vanguard Capital Management LLC | 4.43M | ▼ 6.64K |
| Blackrock, Inc. | 2.56M | ▼ 703.33K |
| Renaissance Technologies LLC | 1.99M | ▼ 75.00K |
| Dafna Capital Management LLC | 1.68M | 0 |
| Fmr LLC | 1.60M | ▲ 219.48K |
| Millennium Management LLC | 1.50M | ▼ 84.41K |
| Silverback Asset Management LLC | 1.45M | 0 |
| Aqr Capital Management LLC | 1.43M | ▼ 1.28M |
Held by 33 ETFs
Biggest fund positions in ARAY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | WHITTERS JOSEPH E | other | 1,415 |
| Nov 13, 26 | WHITTERS JOSEPH E | other | 1,415 |
| Nov 13, 26 | Nishimura Mika | other | 1,415 |
| Nov 13, 26 | Nishimura Mika | other | 1,415 |
| Nov 13, 26 | MAYER STEVEN F | other | 1,415 |
| Nov 13, 26 | MAYER STEVEN F | other | 1,415 |
| Nov 13, 26 | Galbato Chan | other | 1,415 |
| Nov 13, 26 | Galbato Chan | other | 1,415 |
| Nov 13, 26 | Hindman James M. | other | 1,415 |
| Nov 13, 26 | Hindman James M. | other | 1,415 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARAY coverage
Recent articles, reports, and earnings notes.
No research on ARAY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARAY report →Accuray Closes TCW Transaction, Strengthening Balance Sheet to Support Long-Term Value Growth
prnewswire.com · Nov 13
Accuray Incorporated (ARAY) Q1 2027 Earnings Call Transcript
seekingalpha.com · Nov 5
Accuray Announces 1-for-40 Reverse Stock Split
prnewswire.com · Nov 4
Accuray Reports Fiscal 2027 First Quarter Financial Results
prnewswire.com · Nov 4
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
prnewswire.com · Oct 30
Accuray to Report First Quarter Fiscal 2027 Financial Results on November 4, 2026
prnewswire.com · Oct 21
Accuray Stockholders Approve Financing, Share Increase and Reverse Split Authority
defenseworld.net · Oct 7
Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director
prnewswire.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.